293 related articles for article (PubMed ID: 18197627)
1. hERG classification model based on a combination of support vector machine method and GRIND descriptors.
Li Q; Jørgensen FS; Oprea T; Brunak S; Taboureau O
Mol Pharm; 2008; 5(1):117-27. PubMed ID: 18197627
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive support vector machine binary hERG classification model based on extensive but biased end point hERG data sets.
Shen MY; Su BH; Esposito EX; Hopfinger AJ; Tseng YJ
Chem Res Toxicol; 2011 Jun; 24(6):934-49. PubMed ID: 21504223
[TBL] [Abstract][Full Text] [Related]
3. A binary QSAR model for classification of hERG potassium channel blockers.
Thai KM; Ecker GF
Bioorg Med Chem; 2008 Apr; 16(7):4107-19. PubMed ID: 18243713
[TBL] [Abstract][Full Text] [Related]
4. Prospective validation of a comprehensive in silico hERG model and its applications to commercial compound and drug databases.
Doddareddy MR; Klaasse EC; Shagufta ; Ijzerman AP; Bender A
ChemMedChem; 2010 May; 5(5):716-29. PubMed ID: 20349498
[TBL] [Abstract][Full Text] [Related]
5. In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage.
Su BH; Shen MY; Esposito EX; Hopfinger AJ; Tseng YJ
J Chem Inf Model; 2010 Jul; 50(7):1304-18. PubMed ID: 20565102
[TBL] [Abstract][Full Text] [Related]
6. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
Durdagi S; Duff HJ; Noskov SY
J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
[TBL] [Abstract][Full Text] [Related]
7. Classification models for HERG inhibitors by counter-propagation neural networks.
Thai KM; Ecker GF
Chem Biol Drug Des; 2008 Oct; 72(4):279-89. PubMed ID: 18844674
[TBL] [Abstract][Full Text] [Related]
8. Insights for human ether-a-go-go-related gene potassium channel inhibition using recursive partitioning and Kohonen and Sammon mapping techniques.
Ekins S; Balakin KV; Savchuk N; Ivanenkov Y
J Med Chem; 2006 Aug; 49(17):5059-71. PubMed ID: 16913696
[TBL] [Abstract][Full Text] [Related]
9. A novel approach using pharmacophore ensemble/support vector machine (PhE/SVM) for prediction of hERG liability.
Leong MK
Chem Res Toxicol; 2007 Feb; 20(2):217-26. PubMed ID: 17261034
[TBL] [Abstract][Full Text] [Related]
10. Combining cluster analysis, feature selection and multiple support vector machine models for the identification of human ether-a-go-go related gene channel blocking compounds.
Nisius B; Göller AH; Bajorath J
Chem Biol Drug Des; 2009 Jan; 73(1):17-25. PubMed ID: 19152631
[TBL] [Abstract][Full Text] [Related]
11. Determination of hERG channel blockers using a decision tree.
Gepp MM; Hutter MC
Bioorg Med Chem; 2006 Aug; 14(15):5325-32. PubMed ID: 16616507
[TBL] [Abstract][Full Text] [Related]
12. Bias-correction of regression models: a case study on hERG inhibition.
Hansen K; Rathke F; Schroeter T; Rast G; Fox T; Kriegl JM; Mika S
J Chem Inf Model; 2009 Jun; 49(6):1486-96. PubMed ID: 19435326
[TBL] [Abstract][Full Text] [Related]
13. Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Wiśniowska B; Mendyk A; Fijorek K; Glinka A; Polak S
J Appl Toxicol; 2012 Oct; 32(10):858-66. PubMed ID: 22761000
[TBL] [Abstract][Full Text] [Related]
14. ADMET Evaluation in Drug Discovery. 16. Predicting hERG Blockers by Combining Multiple Pharmacophores and Machine Learning Approaches.
Wang S; Sun H; Liu H; Li D; Li Y; Hou T
Mol Pharm; 2016 Aug; 13(8):2855-66. PubMed ID: 27379394
[TBL] [Abstract][Full Text] [Related]
15. A composite model for HERG blockade.
Kramer C; Beck B; Kriegl JM; Clark T
ChemMedChem; 2008 Feb; 3(2):254-65. PubMed ID: 18061919
[TBL] [Abstract][Full Text] [Related]
16. Indexing molecules for their hERG liability.
Rayan A; Falah M; Raiyn J; Da'adoosh B; Kadan S; Zaid H; Goldblum A
Eur J Med Chem; 2013 Jul; 65():304-14. PubMed ID: 23727540
[TBL] [Abstract][Full Text] [Related]
17. GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Ermondi G; Visentin S; Caron G
Eur J Med Chem; 2009 May; 44(5):1926-32. PubMed ID: 19110341
[TBL] [Abstract][Full Text] [Related]
18. The Catch-22 of Predicting hERG Blockade Using Publicly Accessible Bioactivity Data.
Siramshetty VB; Chen Q; Devarakonda P; Preissner R
J Chem Inf Model; 2018 Jun; 58(6):1224-1233. PubMed ID: 29772901
[TBL] [Abstract][Full Text] [Related]
19. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
Hancox JC; McPate MJ; El Harchi A; Zhang YH
Pharmacol Ther; 2008 Aug; 119(2):118-32. PubMed ID: 18616963
[TBL] [Abstract][Full Text] [Related]
20. A novel structure-based virtual screening model for the hERG channel blockers.
Du L; Li M; You Q; Xia L
Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]